Immunologic chemotherapeutic agents comprising antigen binding dimers covalently bound to drugs

Claim 2

A composition of matter comprising an antigen binding dimer containing an anti-tumor antibody specific to a tumor antigen, said dimer covalently bonded to an anti-cancer drug through a functional group on the dimer that is nonessential for antibody activity of the dimer, and through a functional group on the drug that is nonessential for the pharmacological activity of the drug, thereby preserving both the antibody activity of the dimer and the pharmacological activity of the drug.

Claim 3

The composition of matter according to claim 1 wherein the drug is a pharamceutically active antibiotic.

Claim 4

The composition of matter according to claim 1 wherein the drug is a pharmaceutically active antimetabolite.

Claim 5

The composition of matter according to claim 1 wherein the drug is a pharamceutically active alkaloid.

Claim 6

The composition of matter according to claim 1 wherein the drug is a pharmaceutically active alkylating drug.

Claim 7

The composition of matter according to claim 1 wherein the drug is a chemotherapeutic selected from the group consisting of daunomycin, adriamycin, methotrexate, mithramycin, cytosine arabinoside, and 6-azuridine.

Claim 8

The composition of matter according to claim 1 wherein at least one mole of drug is covalently bonded to a mole of dimer.

Claim 9

The composition of matter according to claim 1 wherein the antibody has specificity to a tumor antigen derived from cells of blood.

Claim 10

The composition of matter according to claim 1 wherein the antibody has specificity to tumor antigens from cells derived from bone marrow.

Claim 11

The composition of matter according to claim 1 wherein the antibody has specificity to tumor antigens from cells derived from tissue.

Claim 12

The composition of matter according to claim 1 wherein the dimer is derived from anti-Yac antibodies.

Claim 13

A process for the preparation of an anti-tumor drug covalently bonded to an antigen binding dimer, which process comprises the steps of oxidizing the drug with an oxidizing agent, bonding the oxidized drug to the dimer, and then stabilizing the bond formed by reduction with a reducing agent, to yield an antigen binding dimer possessing antibody activity bonded to a drug possessing pharmacological activity.

Claim 14

A process for the preparation of an anti-tumor drug covalently bonded to an antigen binding dimer, which process comprises the steps of oxidizing the drug with an oxidizing agent, bonding the oxidized drug to the dimer, and then stabilizing the bond formed by reduction with a reducing agent, to yield an antigen binding dimer possessing antibody activity bonded to a drug possessing pharmacological activity.

Claim 15

The process for the preparation of an anti-tumor drug covalently bonded to an antigen binding dimer according to claim 12 wherein the oxidizing agent is sodium periodate, the oxidized drug is bonded to a free amino group of the dimer forming a Schiff's base, and the reducing agent is sodium borohydride.

Claim 16

A process for preparing a pharmaceutical composition of matter comprising an antigen binding dimer formed by the proteolytic enzyme digestion of an immunoglobulin containing an anti-tumor antibody specific to a tumor antigen, said dimer covalently bound to an anti-cancer drug through a functional group on the dimer that is nonessential for the antibody activity of the dimer, and through a functional group on the drug that is nonessential for the pharmacological activity of the drug, and wherein said process comprises the steps of oxidizing the drug with an oxidizing agent, binding the oxidized drug to a free functional group on the dimer, and stabilizing the bonds formed by reduction with a reducing agent thereby producing an antigen binding dimer possessing both the antibody activity of the dimer and the pharmacological activity of the drug.

Claim 17

A process for preparing a pharmaceutical composition of matter comprising an antigen binding dimer formed by the proteolytic enzyme digestion of an immunoglobulin containing an anti-tumor antibody specific to a tumor antigen, said dimer covalently bound to an anti-cancer drug through a functional group on the dimer that is nonessential for the antibody activity of the dimer, and through a functional group on the drug that is nonessential for the pharmacological activity of the drug, and wherein said process comprises the steps of oxidizing the drug with an oxidizing agent, binding the oxidized drug to a free functional group on the dimer, and stabilizing the bonds formed by reduction with a reducing agent thereby producing an antigen binding dimer possessing both the antibody activity of the dimer and the pharmacological activity of the drug.

Claim 18

The process for preparing the composition of matter comprising the antigen binding dimer containing an anti-tumor antibody covalently bound to an anti-cancer drug according to claim 14 wherein the oxidizing agent is sodium periodate, the oxidizing drug is bound to a free amino group of the dimer by a Schiff's base, and the reducing agent is sodium borohydride.

Claim 19

The process for preparing the composition of matter according to claim 14 wherein the drug is a chemotherapeutic selected from the group consisting of alkylating, antibiotic, antimetabolic, and alkaloid drugs, and wherein at least one mole of drug is covalently bonded per mole of antigen binding dimer.

Claim 20

A composition of matter comprising an antigen binding dimer formed from an immunoglobulin selective to a tissue or cell antigen, said dimer covalently bound to a pharmaceutically acceptable drug through a functional group on the dimer that is nonessential for antibody activity, and through a functional group on the drug that is nonessential for the pharmaceutical activity of the drug for simultaneously preserving the antibody activity of the dimer, and the pharmacological activity of the drug.

Claim 21

A composition of matter comprising an antigen binding dimer formed from an immunoglobulin selective to a tissue or cell antigen, said dimer covalently bound to a pharmaceutically acceptable drug through a functional group on the dimer that is nonessential for antibody activity, and through a functional group on the drug that is nonessential for the pharmaceutical activity of the drug for simultaneously preserving the antibody activity of the dimer, and the pharmacological activity of the drug.